Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bromocriptine Mesylate

FDA-approved product (capsule, oral), marketed as Bromocriptine Mesylate, Cycloset, Parlodel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Bromocriptine Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acromegaly
  • Adenoma
  • Hyperprolactinemia
  • Hypogonadism
  • Infertility
  • Parkinson disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Prolactine inhibitors; Dopamine agonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae48.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bromocriptine Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bromocriptine Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME

    NCT03384524 · start 2018-03

    Registered record
    Registry ID
    NCT03384524
    Conditions
    Diabetic Macular Edema
    Interventions
    Bromocriptine 2.5 MG; Metoprolol 25 MG; Tamsulosin 0.4 MG; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2018-03
    Completion
    2019-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Macular Edema
    InterventionBromocriptine 2.5 MG; Metoprolol 25 MG; Tamsulosin 0.4 MG; Placebo
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

    NCT03492580 · start 2018-02-22

    Registered record
    Registry ID
    NCT03492580
    Conditions
    Diabetes Mellitus, Type 2; Cardiovascular Diseases
    Interventions
    Canagliflozin; Empagliflozin; Dapagliflozin; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors; Glucagon-like Peptide-1 (GLP-1) Agonist; Anti-hyperglycemic Agents (AHA); Thiazolidinediones (TZD); Sulfonylureas (SU); Insulin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-02-22
    Completion
    2018-06-25
    Enrolment
    714,582

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Cardiovascular Diseases
    InterventionCanagliflozin; Empagliflozin; Dapagliflozin; Dipeptidyl Peptidase-4 (DPP-4) Inhibitors +5 more
    PhaseNot recorded
    Registry statusCompleted

  • Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM

    NCT05405244 · start 2017-09-19

    Registered record
    Registry ID
    NCT05405244
    Conditions
    Overweight and Obesity; Eating Behavior
    Interventions
    Placebo; Bromocriptine-QR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-19
    Completion
    2019-09-19
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOverweight and Obesity; Eating Behavior
    InterventionPlacebo; Bromocriptine-QR
    PhasePhase 3
    Registry statusCompleted

  • Bromocriptine in the Treatment of Peripartum Cardiomyopathy

    NCT02590601 · start 2017-01-01

    Registered record
    Registry ID
    NCT02590601
    Conditions
    Peripartum Cardiomyopathy
    Interventions
    Bromocriptine; Guideline-driven medical therapy (GDMT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2017-01-01
    Completion
    2023-01-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripartum Cardiomyopathy
    InterventionBromocriptine; Guideline-driven medical therapy (GDMT)
    PhasePhase 3
    Registry statusWithdrawn

  • Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome

    NCT02846493 · start 2016-08

    Registered record
    Registry ID
    NCT02846493
    Conditions
    Ovarian Hyperstimulation Syndrome
    Interventions
    bromocriptine; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2018-06
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Hyperstimulation Syndrome
    Interventionbromocriptine; dexamethasone
    PhasePhase 2
    Registry statusUnknown

  • A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

    NCT02696512 · start 2016-03

    Registered record
    Registry ID
    NCT02696512
    Conditions
    Brain Injury
    Interventions
    Polypharmacy using FDA-approved products; Median Nerve Stimulation (MNS); Nutraceutical Supplementation; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2016-03
    Completion
    2017-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Injury
    InterventionPolypharmacy using FDA-approved products; Median Nerve Stimulation (MNS); Nutraceutical Supplementation; Standard of Care
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Study on Therapy of Non-invasive Prolactinoma

    NCT03353025 · start 2016-01-01

    Registered record
    Registry ID
    NCT03353025
    Conditions
    Prolactinoma
    Interventions
    transsphenoidal surgery treatment; dopamine agonist treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-01-01
    Completion
    2025-12-31
    Enrolment
    394

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProlactinoma
    Interventiontranssphenoidal surgery treatment; dopamine agonist treatment
    PhaseNot applicable
    Registry statusUnknown

  • Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects

    NCT02682901 · start 2015-10-05

    Registered record
    Registry ID
    NCT02682901
    Conditions
    Diabetic Autonomic Neuropathy
    Interventions
    Cycloset; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-10-05
    Completion
    2018-11-15
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Autonomic Neuropathy
    InterventionCycloset; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes

    NCT02544321 · start 2015-09

    Registered record
    Registry ID
    NCT02544321
    Conditions
    Type 1 Diabetes
    Interventions
    Bromocriptine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-09
    Completion
    2019-06
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes
    InterventionBromocriptine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Bromocriptine and Insulin Sensitivity

    NCT02428946 · start 2014-10

    Registered record
    Registry ID
    NCT02428946
    Conditions
    Insulin Sensitivity
    Interventions
    Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-12
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsulin Sensitivity
    InterventionBromocriptine
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study

    NCT02133755 · start 2014-07

    Registered record
    Registry ID
    NCT02133755
    Conditions
    PCOS; Insulin Resistance
    Interventions
    Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2014-07
    Completion
    2015-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPCOS; Insulin Resistance
    InterventionBromocriptine
    PhasePhase 3
    Registry statusUnknown

  • Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

    NCT02299050 · start 2014-06

    Registered record
    Registry ID
    NCT02299050
    Conditions
    Type 2 Diabetes
    Interventions
    Cycloset
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-06
    Completion
    2018-04-30
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionCycloset
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

    NCT02078440 · start 2014-01

    Registered record
    Registry ID
    NCT02078440
    Conditions
    Type 2 Diabetes
    Interventions
    Bromocriptine mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-01
    Completion
    2016-06
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes
    InterventionBromocriptine mesylate
    PhasePhase 1
    Registry statusCompleted

  • To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism

    NCT02265484 · start 2013-11

    Registered record
    Registry ID
    NCT02265484
    Conditions
    Cirrhosis Related Parkinsonism
    Interventions
    Lactulose+Rifaximin +Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-11
    Completion
    2015-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis Related Parkinsonism
    InterventionLactulose+Rifaximin +Bromocriptine
    PhaseNot applicable
    Registry statusCompleted

  • Dopaminergic Effects on Brown Adipose Tissue

    NCT02428933 · start 2013-10

    Registered record
    Registry ID
    NCT02428933
    Conditions
    Obesity
    Interventions
    Bromocriptine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-10
    Completion
    2014-02
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionBromocriptine
    PhaseNot applicable
    Registry statusCompleted